Hyperlipidemia and its management in renal disease

Current Opinion in Nephrology and Hypertension

Volumn 5, Issue 2, 1996, Pages 141-146

  Massy, Ziad A ^a   Kasiske, Bertram L ^a,b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b HENNEPIN COUNTY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CORTICOSTEROID; CYCLOSPORIN; FIBRIC ACID DERIVATIVE; FISH OIL; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

HUMAN; HYPERLIPIDEMIA; KIDNEY DISEASE; REVIEW; CARDIOVASCULAR DISEASE; DIET; DRUG EFFECT; PRIORITY JOURNAL;

ANTILIPEMIC AGENTS; HUMANS; HYPERLIPIDEMIAS; KIDNEY DISEASES;

EID: 0029665978     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-199603000-00007     Document Type: Article

References (63)

1. Keane WF, Kasiske BL: Hyperlipidemia in the nephrotic syndrome. N Engl J Med 1990, 323:604-606.
2. Vega GL, Toto RD, Grundy SM: Metabolism of low density lipoproteins in nephrotic dyslipidemia: Comparison of hypercholesterolemia alone and combined hyperlipidemia. Kidney Int 1995, 47:579-586.
3. Attman P-O, Samuelsson O, Alaupovic P: Lipoprotein metabolism and renal failure. Am J Kidney Dis 1993, 6:573-592.
4. Samuelsson O, Attman P-O, Knight-Gibson C, Kron B, Larsson R, Mulec H, Weiss L, Alaupovic P: Lipoprotein abnormalities without hyperlipidaemia in moderate renal insufficiency. Nephrol Dial Transplant 1994, 9:1580-1585. This study indicates that lipoprotein abnormalities, particularly Apo B-containing lipoproteins, develop early in the course of progressive renal disease. They are not necessarily linked to increased plasma triglyceride levels, and thus may not be detected by routine measurements of plasma lipids alone.
5. Markell MS, Armenti V, Danovitch G, Sumrani N: Hyperlipidemia and glucose intolerance in the post-renal transplant patient. J Am Soc Nephrol 1994, 4:S37-S47.
6. Wanner C, Rader D, Bartens W, Krämer J, Brewer HB, Schollmeyer P, Wieland H: Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome. Ann Intern Med 1993, 119:263-269.
7. Kronenberg F, König P, Neyer U, Auinger M, Pribasnig A, Lang U, Reitinger J, Pinter G, Utermann G, Dieplinger H: Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 1995, 6:110-120.
8. Massy ZA, Bader CA, Chevalier A, Chauveau P, Zingraft J, Lambrey G, Drueke T, Jungers P, Kreis H, Lacour B: Serum lipoprotein(a) levels in chronic renal failure and renal transplant patients. J Nephrol 1994, 7:229-236.
9. Kronenberg F, König P, Lhotta K, Öfner D, Sandholzer C, Margreiter R, Dosch E, Utermann G, Dieplinger H: Apolipoprotein(a) phenotype-associated decrease in lipoprotein(a) plasma concentrations after renal transplantation. Arterioscler Thromb 1994, 14:1399-1404.
10. Massy ZA, Kasiske BL: Chapter 11: The management of hyperlipidemia in patients with renal disease. In International Yearbook of Nephrology Dialysis Transplantation. Edited by Andreucci VE, Fine LG. Oxford: Oxford University Press; 1995:117-125.
11. Maggi E, Bellazzi R, Falaschi F, Frattoni A, Perani G, Finardi G, Gazo A, Nai M, Romanini D, Bellomo G: Enhanced LDL oxidation in uremic patients: an additional mechanism for accelerated atherosclerosis? Kidney Int 1994, 45:876-883.
12. Sutherland WHF, Walker RJ, Ball MJ, Stapley SA, Robertson MC: Oxidation of low density lipoproteins from patients with renal failure or renal transplants. Kidney Int 1995, 48:227-236.
13. Keane WF: Lipids and the kidney. Kidney Int 1994, 46:910-920.
14. Berlyne GM, Mallick NP: Ischaemic heart-disease as a complication of nephrotic syndrome. Lancet 1969, 2:399-400.
15. Alexander JH, Schapel GJ, Edwards KD: Increased incidence of coronary heart disease associated with combined elevation of serum triglyceride and cholesterol concentrations in the nephrotic syndrome in man. Med J Aust 1974, 2:119-122.
16. Wass VJ, Jarrett RJ, Chilvers C, Cameron JS: Does the nephrotic syndrome increase the risk of cardiovascular disease? Lancet 1979, 2:664-667.
17. Curry RC, Roberts WC: Status of the coronary arteries in the nephrotic syndrome. Analysis of 20 necropsy patients aged 15 to 35 years to determine if coronary atherosclerosis is accelerated. Am J Med 1977, 63:183-192.
18. Ordoñez JD, Hiatt RA, Killebrew EJ, Fireman BH: The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 1993, 44:638-642.
19. Stroes ESG, Joles JA, Chang PC, Koomans HA, Rabelink TJ: Impaired endothelial function in patients with nephrotic range proteinuria. Kidney Int 1995, 48:544-550. Screening for an early marker of atherosclerosis in nephrotic patients may be one way to evaluate the pathogenesis and treatment of dyslipidemia in these patients before having cardiovascular events.
20. Smellie WSA, Warwick GL: Primary hyperlipidaemia is not associated with increased urinary albumin excretion. Nephrol Dial Transplant 1991, 6:398-401.
21. Metcalf P, Baker J, Scott A, Wild C, Scragg R, Dryson E: Albuminuria in people at least 40 years old: effect of obesity, hypertension, and hyperlipidemia. Clin Chem 1992, 38:1802-1808.
22. Bianchi S, Bigazzi R, Valtriani C, Chiapponi I, Sgherri G, Baldari G, Natali A, Ferrannini E, Campese VM: Elevated serum insulin levels in patients with essential hypertension and microalbuminuria. Hypertension 1994, 23:681-687.
23. Imbasciati E, Paties C, Scarpioni L, Mihatsch MJ: Renal lesions in familial lecithin-cholesterol acyltransferase deficiency. Am J Nephrol 1986, 6:66-70.
24. Saito T, Sato H, Oikawa S: Lipoprotein glomerulopathy: a new aspect of lipid induced glomerular injury. Nephrology 1995, 1:17-24.
25. Horita K, Eto M, Makino I: Apolipoprotein E2, renal failure and lipid abnormalities in non-insulin-dependent diabetes mellitus. Atherosclerosis 1994, 107:203-211.
26. Cappelli P, Evangelista M, Bonomini M, Palmieri PF, Albertazzi A: Lipids in the progression of chronic renal failure. Nephron 1992, 62:31-35.
27. Krolewski AS, Warram JH, Christlieb AR: Hypercholesterolemia - a determinant of renal function loss and deaths in IDDM patients with nephropathy. Kidney Int 1994, 45(suppl 45):S125-S131.
28. Ravid M, Neumann L, Lishner M: Plasma lipids and the progression of nephropathy in diabetes mellitus type II: effect of ACE inhibitors. Kidney Int 1995, 47:907-910.
29. Samuelsson O, Aurell M, Knight-Gibson C, Alaupovic P, Attman P-O: Apolipoprotein-B-containing lipoproteins and the progression of renal insufficiency. Nephron 1993, 63:279-285.
30. Sato H, Suzuki S, Ueno M, Shimada H, Karasawa R, Nishi S-I, Arakawa M: Localization of apolipoprotein(a) and B-100 in various renal diseases. Kidney Int 1993, 43:430-435.
31. 51Cr-EDTA over a 2- year interval.
32. Lindner A, Charra B, Sherrard DJ, Scribner BH: Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974, 290:697-700.
33. Raine AEG, Margreiter R, Brunner FP, Ehrich JHH, Geerlings W, Landais P, Loirat C, Mallick NP, Selwood NH, Tufveson G, Valderrabano F: Report on management of renal failure in Europe, XXII, 1991. Nephrol Dial Transplant 1992, 7(suppl 2):7-35.
34. Brown JH, Hunt LP, Vites NP, Short CD, Gokal R, Mallick NP: Comparative mortality from cardiovascular disease in patients with chronic renal failure. Nephrol Dial Transplant 1994, 9:1136-1142. This study clearly demonstrated, in a population of patients with chronic renal failure, that the incidence of fatal CVD is over 10 times that of the corresponding general population.
35. Kronenberg F, Kathrein H, König P, Neyer U, Sturm W, Lhotta K, Gröchenig E, Utermann G, Dieplinger H: Apolipoprotein(a) pheno-types predict the risk for carotid atherosclerosis in patients with end-stage renal disease. Arterioscler Thromb 1994, 14:1405-1411. A high prevalence of an early atherosclerotic marker, carotid plaques, was shown in hemodialysis patients. The Apo(a) phenotype was the best predictor of carotid plaque.
36. Kawagishi T, Nishizawa Y, Konishi T, Kawasaki K, Emoto M, Shoji T, Tabata T, Inoue T, Morii H: High-resolution B-mode ultrasonography in evaluation of atherosclerosis in uremia. Kidney Int 1995, 48:820-826.
37. Haaber AB, Eidemak I, Jensen T, Feldt-Rasmussen B, Strandgaard S: Vascular endothelial cell function and cardiovascular risk factors in patients with chronic renal failure. J Am Soc Nephrol 1995, 5:1581-1584.
38. Takagi M, Wada H, Mukai K, Kihira H, Yano S, Minamikawa K, Wakita Y, Nakase T, Nagaya S, Deguchi K et al.: Increased vascular endothelial cell markers in patients with chronic renal failure on maintenance haemodialysis. Blood Coagul Fibrinol 1994, 5:713-717.
39. Fishbane S, Youn S, Kowalski EJ, Frei GL: Ankle-arm blood pressure index as a marker for atherosclerotic vascular diseases in hemodialysis patients. Am J Kidney Dis 1995, 25:34-39.
40. Cressman MD, Heyka RJ, Paganini EP, O'Neil J, Skibinski CI, Hoff HF: Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 1992, 86:475-482.
41. Hill MN, Grossman RA, Feldman HI, Hurwitz S, Dafoe DC: Changes in causes of death after renal transplantation, 1966 to 1987. Am J Kidney Dis 1991, 17:512-518.
42. Lindholm A, Albrechtsen D, Frödin L, Tufveson G, Persson NH, Lundgren G: Ischemic heart disease - major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation 1995, 60:451-457.
43. Kasiske BL, Guijarro C, Massy ZA, Weiderkehr MR, Ma JZ: Cardiovascular disease after renal transplantation. J Am Soc Nephrol 1996, 7:158-165. This study demonstrated that the incidence of CVD continues to be high after renal transplantation, despite new immunosuppression protocols and more effective management of risk factors. The work also demonstrated a close association between ischemic heart disease, cerebral vascular disease, and peripheral vascular disease after renal transplantation, underscoring the importance of aggressive risk factor management in renal transplant patients who develop a vascular disease event.
44. Abdulmassih Z, Chevalier A, Bader C, Drüeke T, Kreis H, Lacour B: Role of lipid disturbances in the atherosclerosis of renal transplant patients. Clin Transplant 1992, 6:106-113.
45. Kasiske BL: Risk factors for accelerated atherosclerosis in renal transplant recipients. Am J Med 1988, 84:985-992.
46. Heule H, Keusch G, Uhlschmid G, Largiader F, Binswanger U: Cardiovascular diseases after kidney transplantation: an analysis of predisposing factors [in German]. Schweiz Med Wochenschr 1981, 20:709-716.
47. Massy ZA, Millet P, Helenon O, Bader CA, Chevalier A, Drüeke T, Moreau J-F, Lacour B, Kreis H: Ultrasonographically assessed carotid plaques: relation with cardiovascular risk factors in renal transplant recipients [Abstract]. J Am Soc Nephrol 1993, 4:948.
48. Gjertson DW: Survival trends in long-term first cadaver-donor kidney transplants. In Clinical Transplants 1990. Edited by Terasaki PI, Cecka JM. Los Angeles: UCLA Tissue Typing Laboratory; 1991:225-235.
49. Knechtle SJ, Pirsch JD, D'Alessandro AM, Sollinger HW, Kalayoglu M, Belzer FO: Renal transplantation at the University of Wisconsin in the cyclosporine era. In Clinical Transplants 1992. Edited by Terasaki PI, Cecka JM. Los Angeles: UCLA Tissue Typing Laboratory; 1993:211-218.
50. Vollmer E, Bosse A, Bögeholz J, Roessner A, Blasius S, Fahrenkamp A, Böcker W: Apolipoproteins and immunohistological differentiation of cells in the arterial wall of kidneys in transplant arteriopathy. Pathol Res Pract 1991, 187:957-962.
51. Charlesworth JA, Edwards KD: Relation of hypertriglyceridaemia to kidney transplant dysfunction and rejection, and response to antilymphocyte globulin therapy. Prog Biochem Pharmacol 1974, 9:107-120.
52. Knight RJ, Kerman RH, Welsh M, Golden D, Schoenberg L, Van Buren CT, Lewis RM, Kahan BD: Chronic rejection in primary renal allograft recipients under cyclosporine-prednisone immunosuppressive therapy. Transplantation 1991, 51:355-359.
53. Markell MS, Sumrani N, Dibenedetto A, Friedman EA: Effect of early hyperlipidemia on graft and patient survival in cyclosporine-treated renal transplant patients. Am J Kidney Dis 1993, 22:233-239.
54. Dimény E, Fellström B, Larsson E, Tufveson G, Lithell H: Chronic vascular rejection and hyperlipoproteinemia in renal transplant patients. Clin Transplant 1993, 7:482-490.
55. Dimény E, Tufveson G, Lithell H, Larsson E, Siegbahn A, Fellström B: The influence of pretransplant lipoprotein abnormalities on the early results of renal transplantation. Eur J Clin Invest 1993, 23:572-579.
56. Isoniemi H, Nurminen M, Tikkanen M, von Willebrand E, Krogerus L, Ahonen J, Eklund B, Höckerstedt K, Salmela K, Häyry P: Risk factors predicting chronic rejection of renal allograft. Transplantation 1994, 57:68-72.
57. Massy ZA, Guijarro C, Wiederkehr MR, Ma JZ, Kasiske BL: Chronic renal allograft rejection: immunologic and nonimmunologic risk factors. Kidney Int 1996, 49:518-524. The use of a proportional hazard analysis with time-dependent covariates allowed the authors to explore the complex interrelationships between immune and non-immune risk factors for chronic renal allograft rejection in the early and late post-transplant period in large cohort of renal transplant patients.
58. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, Chia D, Terasaki PI, Sabad A, Cogert GA et al.: Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995, 333:621-627.
59. Katznelson S, Kobashigawa JA: The dual roles of HMG-CoA reductase inhibitors in solid organ transplantation - lipid lowering and immunosuppression. Kidney Int 1995, 48:S112-S115.
60. Rader DJ, Hoeg JM, Brewer HB Jr: Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Ann Intern Med 1994, 120:1012-1025.
61. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V et al.: Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987, 317:1237-1245.
62. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults: Summary of the Second Report of the National Cholesterol Education Program (NCEP) (Adult Treatment Panel II). JAMA 1993, 269:3015-3023.
63. Massy ZA, Ma JZ, Louis TA, Kasiske BL: Lipid-lowering therapy in patients with renal disease. Kidney Int 1995, 48:188-198. This meta-analysis compared and contrasted the relative efficacy of different lipid-lowering strategies in various clinical settings of renal disease. It included 3065 patients and controls in 198 study groups. The results of this study provide a useful framework for choosing antilipemic therapy in patients with renal disease.